AzTrials
AzTrials

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Phase 3NCT05249816

Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine

A Phase 3 study testing NVX-CoV2373 and BBIBP-CorV vaccine in people with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), run by Cogna Technology Solutions LLC at 2 sites in United Arab Emirates.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is an observer-blinded Phase 3 study to evaluate the safety and immunogenicity of a single booster dose of the Novavax severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine adjuvanted with Matrix-MTM (NVX-CoV2373) in adults previously vaccinated with… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
NVX-CoV2373 and BBIBP-CorV vaccine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,000 participants
Where
2 sitesUnited Arab Emirates
Study dates
18 Mar 2022to 4 May 2023
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adults ≥ 18 years of age, inclusive, at screening.
  • Willing and able to give informed consent prior to study enrollment and to comply with study procedures.
  • Females of childbearing potential (defined as any female who has experienced menarche) who is NOT surgically sterile (i.e., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (defined as amenorrhea at least 12 consecutive months), must agree to either be heterosexually inactive OR consistently use a medically acceptable method of contraception, from enrollment and to 3 months after the last vaccination. Medically acceptable methods of contraception include:
  • Condoms (male or female)
  • Diaphragm with spermicide
  • Cervical cap with spermicide
Show all 15Show fewer
  • Intrauterine device
  • Oral or patch contraceptives
  • Norplant®, Depo-Provera®, or other in country regulatory approved contraceptive method that is designed to protect against pregnancy
  • Abstinence, as a form of contraception, is acceptable if in line with the participant's lifestyle
  • NOTE: Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post- ovulation methods) and withdrawal are not acceptable methods of contraception.
  • Condoms (male or female) are not required if a female partner is using an alternative medically acceptable method of contraception as listed in points 3a-g).
  • Is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges as determined by the investigator prior to the first vaccination.
  • Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study. NOTE: For participants who become hospitalized with COVID-19, participation in investigational treatment studies is permitted.
  • Has previously received a documented complete two dose series of the BBIBP-CorV vaccine with the second dose having been given at least 180 days prior to study vaccination OR has previously received a documented complete two dose series of the BBIBP-CorV vaccine and a third dose booster of BBIBP-CorV vaccine, with the third dose having been given at least 90 days prior to study vaccination.

Who cannot join

  • Participation in research involving receipt of investigational products (drug/biologic/device) within 90 days prior to first study vaccination.
  • Has previously received a primary series vaccination or booster dose of any COVID- 19 vaccine other than BBIBP-CorV.
  • Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine (including COVID-19) within 30 days prior to first study vaccination.
  • Any known allergies to products contained in the investigational product
  • Any history of anaphylaxis to any prior vaccine.
  • Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) requiring ongoing immunomodulatory therapy. NOTE: Stable endocrine disorders (eg, thyroiditis, pancreatitis), including stable diabetes mellitus with no history of diabetic ketoacidosis are NOT excluded.
Show all 15Show fewer
  • Chronic administration (defined as > 14 continuous days) of immunosuppressant, systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to first study vaccination. NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose
  • ≥ 10 mg of prednisone per day or equivalent. The use of topical or intranasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted.
  • Use of inhaled glucocorticoids is prohibited.
  • Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to first study vaccination.
  • Active cancer (malignancy) on therapy within 3 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
  • Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of study.
  • Suspected or known history of alcohol abuse or drug addiction within 2 years prior to the first study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
  • Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
  • Study team member or immediate family member of any study team member (inclusive of Sponsor, CRO, and study site personnel involved in the conduct or planning of the study)

Trial locations and contacts

2 sites in 1 country.

United Arab Emirates2 sites

  • Cleveland Clinic Abu Dhabi

    Abu Dhabi

  • Sheikh Khalifa Medical City (SKMC)

    Abu Dhabi

Other trials in United Arab Emirates

About this study

Official title: An Observer-Blinded Phase 3 Study to Evaluate the Safety and Immunogenicity of a Single Booster of the NVX-CoV2373 Vaccine in Adults Previously Vaccinated With the BBIBP-CorV Vaccine

This is an observer-blinded Phase 3 study to evaluate the safety and immunogenicity of a single booster dose of the Novavax severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine adjuvanted with Matrix-MTM (NVX-CoV2373) in adults previously vaccinated with the BBIBP-CorV vaccine. The study will enroll approximately1,000 participants >18 years of age. All participants will be randomized in a 1:1 ratio to receive a single booster dose of NVX-CoV2373 or the BBIBP-CorV vaccine. All participants will receive the booster dose on Day 0 and remain on study for immunogenicity and safety data collection through Day 180. An interim analysis will be performed of safety and immunogenicity data gathered through Day 28.

Read the detailed description

Novavax, Inc., is developing recombinant vaccines adjuvanted with the saponin-based Matrix-M for the prevention of disease caused by SARS-CoV-2. Both nonclinical and clinical data to date (Liu 2011; Keech 2020; Formica 2021; Heath 2021) support continued clinical development of SARS-CoV-2 rS vaccines combined with Matrix-M adjuvant as potential vaccines against SARS-CoV-2.

Due to waning immunity following primary vaccination against SARS-CoV-2 as well as the emergence of SARS-CoV-2 variants (eg, Alpha, Beta, Gamma, Delta and Omicron), a number of countries have administered or are planning to administer booster doses of vaccine to either specific subgroups or to their general population. As part of this effort, both homologous boosting (boosting with the same vaccine used for the primary vaccination series) or heterologous boosting (boosting with a vaccine that differs from that used for the primary vaccination series) are being evaluated.

The present study aims to investigate the safety and immunogenicity of a single booster of NVX-CoV2373 administered to participants who have already been immunized with BBIBP-CorV vaccine. The NVX-CoV2373 booster will be administered > 180 days after the second dose of BBIBP-CorV vaccine, and the ability of the vaccine to increase antibody titers against the prototype SARS-CoV-2 strain as well as the ability to induce cross-neutralizing antibodies to variant strains will be evaluated. If favorable immunogenicity and safety profiles are observed following a booster dose of NVX-CoV2373, this option would add flexibility to the global COVID-19 vaccination effort and potentially decrease the need to develop variant-specific vaccines.

Being tested
NVX-CoV2373, BBIBP-CorV vaccine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NVX-CoV2373Biological

    Also called Novavax

    A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant

  • BBIBP-CorV vaccineBiological

    Also called Sinopharm BBIBP-CorV

    BBIBP-CorV vaccine administered per manufacturer instructions.

Study groups in NCT05249816
Study groupRoleWhat they receive
NVX-CoV2373ExperimentalNVX-CoV2373 (5 μg): Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg antigen and 100 μg adjuvant per mL. The vaccination regimen will comprise of 1 intramuscular (IM) injection on Day 0 of 0.5 mL injection volume at a dose of 5 μg of antigen with 50 μg Matrix-M adjuvant.
Receives: Biological: NVX-CoV2373
BBIBP CorVActive comparatorSinopharm BBIBP-CorV vaccine administered per manufacturer instructions as a single intramuscular injection.
Receives: Biological: BBIBP-CorV vaccine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Utilizing ratio of IgG GMTs and difference in seroconversion rates to compare IgG antibody responses between the vaccines.

    Comparative IgG antibody responses on Day 14, summarized in terms of the ratio of IgG GMTs and difference in seroconversion rates (SCR; defined as ≥ 4-fold increase from baseline booster dose) between the vaccines. Non-inferiority will be demonstrated if:

    • The lower bound of the two-sided 95% CI on the ratio of the GMTS (GMTNVX-CoV2373/GMTBBIBP-CorV) is ≥ 0.6667, AND
    • The lower bound of the two-sided 95% CI on the difference between the SCRs (SCRNVX-CoV2373 - SCR BBIBP-CorV) is ≥ 10%.

    Measured: On Day 14.

  2. Utilizing Case Report Forms and safety follow up via telephone to measure and assess incidence, duration, and severity of solicited local and systemic adverse events (AEs)

    All safety analyses will be summarized descriptively by vaccine group using the Safety Analysis Set. To compare the overall safety, the two-sided 95% CIs for the difference of incidence of solicited AEs for 7 days following each vaccination. Recording of solicited and unsolicited AEs may be conducted by electronic data capture (EDC)/reporting. All AEs will be followed until resolution or until clinically stable.

    Measured: For 7 days following each vaccination.

  3. Utilizing Case Report Forms to measure and assess Incidence, duration, severity, and relationship of unsolicited AEs

    All safety analyses will be summarized descriptively by vaccine group using the Safety Analysis Set. 1085BUnsolicited AEs will be coded by preferred term and system organ class using MedDRA and summarized by vaccine group as well as by severity and relationship to booster vaccine. Unsolicited AEs through 28 days after the booster vaccination. Recording of solicited and unsolicited AEs may be conducted by electronic data capture (EDC)/reporting. All AEs will be followed until resolution or until clinically stable.

    Measured: Through 28 days after the last vaccination.

  4. Utilizing Case Report Forms to measure incidence and relationship of medically attended adverse events (MAAEs), adverse events of special interest (AESIs) (predefined list), and serious adverse events (SAEs) throughout the study.

    To compare the overall safety of a single booster injection of NVX-CoV2373 with Matrix-M adjuvant with a single booster injection of BBIBP-CorV in participants previously vaccinated with a primary two-dose series of the BBIBP-CorV vaccine. Recording of solicited and unsolicited AEs may be conducted by electronic data capture (EDC)/reporting. All AEs will be followed until resolution or until clinically stable.

    Measured: Throughout the study. Note: Beginning on Day 29, only MAAEs related to the vaccine will be recorded.

Secondary outcomes (1)

  1. Utilizing Plaque Reduction Neutralization Tests (PRNT) to compare neutralizing antibody responses

    Objective: Utilize Plaque Reduction Neutralization Tests (PRNT) to compare neutralizing antibody responses to the SARS-CoV-2 rS with Matrix M adjuvant vaccine to antibody responses to the BBIBP-CorV vaccine, both administered as single booster doses, in adult participants ≥18 years of age who were previously vaccinated with a primary two-dose series of BBIBP-CorV.

    Measured: • PRNT GMTs to the SARS-CoV-2 S protein at Days 0, 14, 28, and 180. • GMFRPost/Pre, defined as the ratio of post-vaccination to pre-vaccination (Day 0) PRNT GMTs within the same treatment arm at Days 14, 28, and 180.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2022
  2. Study start18 Mar 2022
  3. Primary completion4 May 2023
  4. Study completion4 May 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
1,000 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05249816
Sponsor's protocol ID
G42-HC-2021001
Status last verified
Aug 2023
First submitted
18 Feb 2022
Last updated
2 Aug 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Formica N, Raburn Mallory R, Gary Albert A, et al, for the 2019nCoV-101 Study Group. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv. 2021; doi: https://doi.org/10.1101/2021.02.26.21252482.

  • Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, Portnoff AD, Massare MJ, Frieman MB, Piedra PA, Ellingsworth L, Glenn G, Smith G. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 Nov 25;38(50):7892-7896. doi: 10.1016/j.vaccine.2020.10.064. Epub 2020 Oct 23.

    PubMed 33139139

  • Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021 Sep 23;385(13):1172-1183. doi: 10.1056/NEJMoa2107659. Epub 2021 Jun 30.

    PubMed 34192426

  • Keech C, Albert G, Reed P, et al, First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. medRxiv 2020.08.05.20168435; doi: https://doi.org/10.1101/2020.08.05.20168435.

  • Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine. 2011 Sep 2;29(38):6606-13. doi: 10.1016/j.vaccine.2011.06.111. Epub 2011 Jul 14.

    PubMed 21762752

  • Toback S, Marchese AM, Warren B, Ayman S, Zarkovic S, ElTantawy I, Mallory RM, Rousculp M, Almarzooqi F, Piechowski-Jozwiak B, Bonilla MF, Bakkour AE, Hussein SE, Al Kaabi N. Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine. Vaccine. 2024 Mar 7;42(7):1777-1784. doi: 10.1016/j.vaccine.2024.02.037. Epub 2024 Feb 15.

    PubMed 38365482

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing NVX-CoV2373 and BBIBP-CorV vaccine in people with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), run by Cogna Technology Solutions LLC at 2 sites in United Arab Emirates.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Utilizing ratio of IgG GMTs and difference in seroconversion rates to compare IgG antibody responses between the vaccines. (time frame: On Day 14.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05249816, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in